Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC.BCLI · Entity 7869 | EVP, CFO and Treasurer | December 30, 2020 | January 01, 2021 |
| Cidara Therapeutics, Inc.CDTX · Entity 69639 | Chief Financial Officer | September 30, 2024 | October 02, 2024 |
| Elicio Therapeutics, Inc.ELTX · Entity 299 | See Remarks | July 16, 2026 | July 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRAINSTORM CELL THERAPEUTICS INC.
Report date December 30, 2020 · Filed January 01, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,600 |
Reported balance
After 2020-12-30 transaction · row 1
1 source rowRow 1 · 2020-12-30 · Tax withholding · Disposed 25,000 · Balance 11,600 F1: Reflects shares of common stock withheld by the issuer to satisfy tax withholding obligations in connection with the vesting of a previously reported restricted stock award. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects shares of common stock withheld by the issuer to satisfy tax withholding obligations in connection with the vesting of a previously reported restricted stock award.
Cidara Therapeutics, Inc.
Report date September 30, 2024 · Filed October 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.75 · Expires 2034-09-29 | Direct | 130,087 |
Reported balance
After 2024-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-09-30 · Grant · Acquired 130,087 · Balance 130,087 F1: The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of September 30, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of September 30, 2024.
Elicio Therapeutics, Inc.
Report date July 16, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.20 · Expires 2036-07-16 | Direct | 60,833 |
Reported balance
After 2026-07-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-16 · Grant · Acquired 60,833 · Balance 60,833 F1: The stock option vests and becomes exercisable as to 50% of the options on July 16, 2027, the first anniversary of the grant date, and as to the remaining 50% of the options on July 16, 2028, the second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable as to 50% of the options on July 16, 2027, the first anniversary of the grant date, and as to the remaining 50% of the options on July 16, 2028, the second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2026 Filed Jul 17, 2026 20:13 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 60,833 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001787403-26-000002 · wk-form4_1784319224.xml · derivative · entry 1 Shah Preetam · CIK 0001787403 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,833 Underlying: Common Stock · 60,833 shares Expires 2036-07-16 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 50% of the options on July 16, 2027, the first anniversary of the grant date, and as to the remaining 50% of the options on July 16, 2028, the second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:40 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 47,900 | $0.00 Strike: $8.10 | $0.00 |
DisclosureSEC source: 0001601485-26-000008 · wk-form4_1770154812.xml · derivative · entry 2 Shah Preetam · CIK 0001787403 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,900 Underlying: Common Stock · 47,900 shares Expires 2036-02-02 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the options on February 2, 2027, the first anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:40 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantCommon Stock | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001601485-26-000008 · wk-form4_1770154812.xml · nonDerivative · entry 1 Shah Preetam · CIK 0001787403 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 F1 · shares: Represents restricted stock units ("RSUs") that will vest as to 25% of the RSUs on February 2, 2027, the first anniversary of the grant date, with the remaining RSUs vesting in annual installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Each RSU represents the right to receive one share of common stock, par value $0.01 per share, of the Issuer. F1 · price: Represents restricted stock units ("RSUs") that will vest as to 25% of the RSUs on February 2, 2027, the first anniversary of the grant date, with the remaining RSUs vesting in annual installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Each RSU represents the right to receive one share of common stock, par value $0.01 per share, of the Issuer. Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 21:12 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 191,624 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001601485-25-000065 · wk-form4_1744837936.xml · derivative · entry 1 Shah Preetam · CIK 0001787403 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,624 Underlying: Common Stock · 191,624 shares Expires 2035-04-15 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the options on March 24, 2025, the first anniversary of the Reporting Person's start date, with the remaining options vesting in equal monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 17:19 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantEmployee Stock Option (right to buy) · Derivative | 130,087 | $0.00 Strike: $10.75 | $0.00 |
DisclosureSEC source: 0001610618-24-000131 · wk-form4_1727903945.xml · derivative · entry 1 Shah Preetam · CIK 0001787403 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,087 Underlying: Common Stock · 130,087 shares Expires 2034-09-29 F1 · derivative.exercise_date: The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of September 30, 2024. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 18:48 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantEmployee Stock Option (right to buy) · Derivative | 217,500 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001610618-24-000026 · wk-form4_1710974888.xml · derivative · entry 2 Shah Preetam · CIK 0001787403 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,500 Underlying: Common Stock · 217,500 shares Expires 2034-03-14 F2 · derivative.exercise_date: The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 15, 2024. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 18:48 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantCommon Stock | 108,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001610618-24-000026 · wk-form4_1710974888.xml · nonDerivative · entry 1 Shah Preetam · CIK 0001787403 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 335,960 F1 · shares: Represents time-based Restricted Stock Units (RSUs) granted on March 15, 2024. All RSUs vest in three equal annual installments, with 1/3 vesting on each of March 10, 2025, 2026, and 2027, subject to continuous service through each such vesting date. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 21:45 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | SaleCommon Stock | 18,931 | $0.67 | $12,679.98 |
DisclosureSEC source: 0001610618-24-000009 · wk-form4_1710294327.xml · nonDerivative · entry 1 Shah Preetam · CIK 0001787403 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,210 F1 · kind: The sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.66 to $0.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F3 · balance_after: Includes 8,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP) on May 19, 2023 and November 20, 2023. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 17:24 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantEmployee Stock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001610618-23-000028 · wf-form4_168012506014993.xml · derivative · entry 2 Shah Preetam · CIK 0001787403 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2033-03-26 F2 · derivative.exercise_date: The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 27, 2023. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 17:24 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610618-23-000028 · wf-form4_168012506014993.xml · nonDerivative · entry 1 Shah Preetam · CIK 0001787403 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,141 F1 · shares: Represents time-based Restricted Stock Units (RSUs) granted on March 27, 2023. All RSUs vest in three equal annual installments, with 1/3 vesting on each of March 10, 2024, 2025, and 2026, subject to continuous service through each such vesting date. Read SEC document |
| March 13, 2023 Filed Mar 13, 2023 21:20 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | SaleCommon Stock | 6,648 | $1.53 | $10,171.44 |
DisclosureSEC source: 0001610618-23-000011 · wf-form4_167875683891628.xml · nonDerivative · entry 1 Shah Preetam · CIK 0001787403 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,141 F1 · kind: The sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · balance_after: Includes 4,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan ("ESPP") on November 18, 2022. Read SEC document |
| September 19, 2022 Filed Sep 19, 2022 20:28 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | SaleCommon Stock | 15,642 | $0.77 | $12,034.95 |
DisclosureSEC source: 0001610618-22-000081 · wf-form4_166363368557923.xml · nonDerivative · entry 2 Shah Preetam · CIK 0001787403 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,789 F3 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units on September 15, 2022. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:28 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | Exercise / conversionRestricted Stock Unit · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610618-22-000081 · wf-form4_166363368557923.xml · derivative · entry 3 Shah Preetam · CIK 0001787403 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2022-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of common stock of the Issuer. F5 · derivative.exercise_date: On September 1, 2021, the Reporting Person was granted restricted stock units totaling 50,000 shares subject to vesting upon the achievement of various milestones. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:28 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | Exercise / conversionCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610618-22-000081 · wf-form4_166363368557923.xml · nonDerivative · entry 1 Shah Preetam · CIK 0001787403 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,431 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person was previously granted restricted stock units to vest upon the achievement of certain milestone events that occurred on September 15, 2022. F2 · balance_after: Includes 4,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2022. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 17:21 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantEmployee Stock Option (right to buy) · Derivative | 102,500 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001610618-22-000029 · wf-form4_164910727375649.xml · derivative · entry 4 Shah Preetam · CIK 0001787403 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,500 Underlying: Common Stock · 102,500 shares Expires 2032-03-30 F4 · derivative.exercise_date: The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 31, 2022. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 17:21 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | Tax withholdingCommon Stock | 24,820 | $0.83 | $20,600.60 |
DisclosureSEC source: 0001610618-22-000029 · wf-form4_164910727375649.xml · nonDerivative · entry 3 Shah Preetam · CIK 0001787403 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,431 F3 · shares: Shares withheld for taxes on RSU vesting. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 17:21 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantCommon Stock | 66,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001610618-22-000029 · wf-form4_164910727375649.xml · nonDerivative · entry 2 Shah Preetam · CIK 0001787403 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,251 F2 · shares: Represents RSUs granted on March 31, 2022. All RSUs are fully vested as of the grant date. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 17:21 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantCommon Stock | 51,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001610618-22-000029 · wf-form4_164910727375649.xml · nonDerivative · entry 1 Shah Preetam · CIK 0001787403 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,250 F1 · shares: Represents time-based Restricted Stock Units (RSUs) granted on March 31, 2022. All RSUs vest in three equal annual installments, with 1/3 vesting on each of March 10, 2023, 2024, and 2025, subject to continuous service through each such vesting date. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 18:38 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | PurchaseCommon Stock | 20,000 | $1.54 | $30,800.00 |
DisclosureSEC source: 0001610618-21-000106 · wf-form4_163701945046603.xml · nonDerivative · entry 1 Shah Preetam · CIK 0001787403 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 16:32 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantRestricted Stock Unit · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610618-21-000082 · wf-form4_163070111456972.xml · derivative · entry 2 Shah Preetam · CIK 0001787403 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2022-09-30 F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSU will fully vest upon the completion of certain corporate milestones on or before September 30, 2022. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 16:32 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantStock Option (right to buy) · Derivative | 311,850 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001610618-21-000082 · wf-form4_163070111456972.xml · derivative · entry 1 Shah Preetam · CIK 0001787403 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,850 Underlying: Common Stock · 311,850 shares Expires 2031-08-31 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date of September 1, 2021; 1/48th of the shares subject to the option shall vest monthly thereafter,such that all shares will be vested on September 1, 2025. Read SEC document |
| December 30, 2020 Filed Jan 1, 2021 02:20 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | Tax withholdingCommon Stock | 25,000 | $4.64 | $116,000.00 |
DisclosureSEC source: 0001104659-20-141128 · tm2039739-1d4.xml · nonDerivative · entry 1 Shah Preetam · CIK 0001787403 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,600 F1 · shares: Reflects shares of common stock withheld by the issuer to satisfy tax withholding obligations in connection with the vesting of a previously reported restricted stock award. Read SEC document |
| December 24, 2019 Filed Dec 27, 2019 12:01 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | PurchaseCommon Stock | 11,600 | $3.96 | $45,929.04 |
DisclosureSEC source: 0001104659-19-076290 · tm1927404-2_4.xml · nonDerivative · entry 1 Shah Preetam · CIK 0001787403 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,600 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.89 to $3.9789, inclusive. The reporting person undertakes to provide to Brainstorm Cell Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 12:00 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001144204-19-043864 · tv529006_4.xml · derivative · entry 3 Shah Preetam · CIK 0001787403 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-09-05 F2 · derivative.exercise_date: Option shall vest and become exercisable as to 25% of the underlying shares on the first anniversary of the date of grant, and the remaining shares underlying the option shall vest and become exercisable in equal quarterly installments thereafter, until fully vested and exercisable on the fourth anniversary of the date of grant, provided Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 12:00 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.96 | $0.00 |
DisclosureSEC source: 0001144204-19-043864 · tv529006_4.xml · derivative · entry 2 Shah Preetam · CIK 0001787403 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-09-05 F2 · derivative.exercise_date: Option shall vest and become exercisable as to 25% of the underlying shares on the first anniversary of the date of grant, and the remaining shares underlying the option shall vest and become exercisable in equal quarterly installments thereafter, until fully vested and exercisable on the fourth anniversary of the date of grant, provided Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 12:00 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-043864 · tv529006_4.xml · nonDerivative · entry 1 Shah Preetam · CIK 0001787403 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · shares: Shares acquired are shares of restricted stock awarded on September 6, 2019 under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 100% of the award on September 6, 2020, provided that the Reporting Person remains continuously employed by Issuer from the date of grant through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.